Skip to main content


Charcot-Marie-Tooth Disease Market Analysis Charcot-Marie-Tooth Disease is estimated to have a global prevalence of 2.6 million worldwide (NINDS). As per DelveInsight, the total Charcot-Marie-Tooth prevalence in the 7MM (the US, EU5, and Japan) was 263,835 in 2020 which is expected to increase in the coming years. As per DelveInsight, the Charcot-Marie-Tooth therapy market is expected to surge at a CAGR of 25.42% for the study period 2018–2030, with the USA accounting for the majority of the market share in the 7MM. To fulfill the therapeutics need, some of the key pharmaceutical companies such as PharNext, MedDayPharma, among others are proactively working in the domain; however, the Charcot-Marie-Tooth disease pipeline constitutes only a few therapeutic agents in advanced stages of clinical trials.